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Abstract
The coronavirus disease 2019 (COVID-19) virus has spread all over the world. Scientists are trying 
to discover drugs as effective treatment for patients with COVID-19. So far about 30 drugs have 
been introduced that one of them is Tocilizumab. Recently Tocilizumab has been introduced to 
treat patients with COVID-19 and researchers are investigating further the efficacy of this drug for 
different are patients. In Iran and China, some reports showed a positive effect of Tocilizumab on 
Saturation of Peripheral Oxygen (SPO2) but results of CT scan in patients in different. In some 
patients, CT scan showed reduced infiltration, however in other no change was observed. 
Unfortunately, until now there has been no definitive and effective treatment for patients with 
COVID-19. Although Tocilizumab has been accepted by China Health Commission to treat 
infected patients, its positive effects still cannot be predicted in all patients.  Based on evidence of 
the Tocilizumab’s effect on the SARS COV 2, researchers hope this drug will make effective and 
promising treatment to improve lung tissue inflammation in patients with the fatal COVID-19 
virus. The present study provides an overview of respiratory inflammation with COVID-19 and 
probable effect of Tocilizumab on SARS-COV 2.
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Background 
Two known zoonotic coronaviruses, SARS-CoV and MERS-CoV, have been reported to damage 
the respiratory tract and cause severe outbreaks in the past decade (1-3). The coronavirus disease 
2019 (COVID-19) virus, emerged in December 2019 in Wuhan, China (4). On Jan 30, 2020, WHO 
declared the current novel coronavirus disease 2019 (COVID-19) as the sixth public health 
emergency epidemic (5) This virus has rapidly spread in china, japan, South Korea and with cases 
now confirmed in many countries  (4, 6).
Common symptoms at the onset of the disease include fever, cough, myalgia, fatigue, dyspnea and 
diarrhea (7). Most of the patients developed pneumonia, which can rapidly worsen into respiratory 
failure and develop Acute Respiratory Distress Syndrome (ARDS) (7, 8). Higher susceptibility 
and mortality was observed in elderly and patients with low immune function (9). According to a 
report, Yang X and colleague, the mortality for critical cases with ARDS increased and reached 
60.5% (10). 
Researchers are discovering new drugs to treat this emerging virus.  So far about 30 drugs have 
been introduced to treat patients with COVID-19 such as Lopinavir, Ritonavir, Oseltamivir, and 
Ganciclovir (9). There is a classification of used drugs to treat respiratory infections from COVID-
19 and stratified into three categories: 1. immune system enhancement (Interfron, Glubolin), 
2.Chloroquine phosphate, 3. Antiviral components (11). Tocilizumab (a humanized anti-IL-6 
receptor antibody) is one of drugs discussed for the treatment of these patients (12).  Xiaoling Xu 
and colleagues conducted a clinical trial study in china and demonstrated that Tocilizumab is 
effective treatment in patients with severe COVID-19 (13). The current study reviews respiratory 
inflammation with COVID-19 and probable effect of Tocilizumab on SARS-COV 2.
What’s the mechanism of respiratory inflammation with COVID-19?
Although, the exact mechanism of immunology that reinforces the potential damages of the 
respiratory system with COVID-19 has not been elucidated, but based on SARS COV, we can 
describe it (13). CD4+ T lymphocytes are rapidly activated and-differentiated into T helper and 
generate granulocyte-macrophage colony-stimulating factor (GM-CSF). The cytokine 
environment provides inflammatory monocytes with a high production of inflammatory cytokines 
such as IL-6 (14). In the observations, large amounts of inflammatory cells infiltrate into the lungs 
of patients with COVID-19.  This process may be responsible for an immune damaging and 
causing lung functional injuries and quick mortality (15).
According to the studies in ICU patients with COVID-19, higher plasma levels of cytokines 
including IL-6, IL-2, IL-7, IL-10, granulocyte-colony stimulating factor (G-CSF), interferon-γ-
inducible protein (IP10), monocyte chemoattractant protein (MCP1), macrophage inflammatory 
protein 1 alpha (MIP1A), and tumor necrosis factor alpha (TNF- α ) were found (7, 16). This 
increase of inflammatory cytokine levels occurs as cytokine storm and is related to the severity 
and prognosis of the disease (16).
Role of IL-6 in lung fibrosis
IL-6 is produced in response to tissue injuries and various types of infections and contributes to 
host defense through activation of immune responses and stimulation of acute phase reactions. IL-
6 is of great importance in the pathogenesis of various inflammatory diseases including infectious 
inflammations associated with tissue fibrosis and for this reason, tocilizumab, anti-IL-6 receptor 
antibody, has been developed. IL-6 binds to the membrane IL-6 receptor (IL-6R) which is only 
expressed on hepatocytes and some of the leukocytes and leads to classical signaling through the 
membrane-bound β-receptor glycoprotein 130 (gp130) (17, 18). There is another pathway, called 
trans-signaling, such that IL-6 binds to soluble forms of the IL-6R (sIL-6R), and this complex, IL-
6/sIL-6R, can activate all of the tissue cells due to the expression of gp130 on all cells (17, 19). In 
this section, we review the role of IL-6 in lung inflammation and fibrosis. 
Saito and colleagues revealed the significance of IL-6 production in the infiltration of 
inflammatory cells in Broncho alveolar lavage fluid of wild-type and IL-6-deficient mice were 
treated with bleomycin. The number of neutrophils and macrophages decreased in BAL fluid in 
IL-6-deficient mice. In addition, lung pathology showed a decrease of the accumulation of 
inflammatory cells in IL-6-deficient mice compared with wild type. These findings revealed the 
significant role of IL-6 in the pathogenesis of bleomycin-induced lung injury and lung fibrosis 
(17).
Le and colleagues evaluated the importance of soluble IL-6Ra in idiopathic pulmonary fibrosis 
(IPF). The increase of soluble IL-6Ra was observed in mice during the onset and progression of 
fibrosis as well as patients with IPF.  Neutralization of soluble IL-6Ra attenuated fibrosis in mice 
by a decrease in collagen, myofibroblasts and fibronectin in the lung. In addition, it has been shown 
that the production of soluble IL6Ra from macrophages interfere with IL-6 trans signaling and 
affect fibrosis in lung tissue. These results indicate the recovery of lung fibrosis by neutralization 
of soluble IL-6Ra (18).  Another study was performed by Kobayashi et al. who investigated the 
neutralizing effect of anti-IL-6 antibody on lung injury induced by bleomycin in mice. Inhibition 
of the early increase of IL-6 by IL-6 neutralizing antibody promoted apoptosis of type 2 
pneumocytes and infiltration of neutrophils and presented lung fibrosis. However, inhibition of the 
second increase of IL-6 by IL-6-neutralizing antibody recovered fibrosis in the lung. The results 
of this study showed that IL-6 could have a bidirectional role in the pathogenesis of lung fibrosis 
in animal models (19). 
Tocilizumab 
Tocilizumab known as traditional Actemra and Atlizumab is an immunosuppressive humanized 
monoclonal antibody drug (20-6). This drug is mainly used for the treatment of rheumatoid arthritis 
(RA) and systemic juvenile idiopathic arthritis (21, 22). Tocilizumab selectively and competitively 
binds to soluble expressing the IL-6 receptor (IL-6) and then blocking the signaling caused by IL- 
6 (21). This drug displays dose-dependent, nonlinear pharmacokinetics and has a long elimination 
half-life (22). Mechanism of Tocilizumab for inhibiting IL-6 receptors is shown in fig 1. 
The elimination of Tocilizumab has been relatively slow and dependent on concentration. After 
saturating the IL6 receptors, clearance of dependent begins by the mononuclear phagocyte system. 
It has been shown that increase of the dose leads to prolongation of the half-life, but it should be 
considered that the elimination of Tocilizumab is capacity limited (6). In a review study of 
Sheppard and colleagues (2017), effects of gender, age, ethnicity, mild renal failure and treatment 
with methotrexate, NSAIDs or corticosteroids on the pharmacokinetics of Tocilizumab were 
unclear (22). 
What is Tocilizumab medical use and side effect?
Tocilizumab is prescribed to treat moderate to severe active arthritis in adults, Giant cell arthritis, 
Polyarticular juvenile idiopathic arthritis and cytokine release syndrome in patients 2 years of age 
older with active disease (23, 24). The recommended dose of Tocilizumab is 4-8 mg/kg 
administered as a single 60- minute intravenous infusion every 4 weeks. This drug should be stored 
refrigerated at 2 to 8 c (36 to 46 F) (24).
Individuals with active infections should not be treated with Tocilizumab. There are no adequate 
studies of Tocilizumab in the pregnant women. Also, it is not known whether Tocilizumab is 
excreted in breast milk (23). 
We can categories side effects into 1) common side effects (respiratory tract infections, headache, 
hypertension, elevation in liver test), 2) reactions of injection site (rash, redness, swelling, itching), 
3) associated serious infection (tuberculosis, sepsis, fungal infection), 4) side effects reported in 
studies (hyper sensitivity reactions, developed cancer, reactivation of herpes zoster, 
gastrointestinal perforation in patients with diverticulitis) (22, 24).
About side effects of Tocilizumab in infected patient with coronavirus, initial researches did not 
reveal any side effects. Although may be reported longer time side effects.  
Tocilizumab; treatment of COVID-19 infection
Tocilizumab inhibits IL-6- receptor, witch as described above is a key cytokine leading to an 
inflammatory storm which may result in increased alveolar-capillary blood-gas exchange 
dysfunction, especially impaired oxygen diffusion, and eventually lead to pulmonary fibrosis and 
organ failure. (25- 27) Based on some reports, Tocilizumab can be a suitable and effective drug 
for COVID-19 patients. (28-30)
As mentioned in table 1, to date some studies such as case reports, retrospective studies, and 
clinical trial about effectiveness of Tocilizumab in COVID-19 have been published in many 
affected countries i.e. China, France, Italy, Switzerland and Qatar (13, 30-39). However, still no 
evidence based study confirms efficacy of treatment with this drug. Some researchers have even 
criticized the use of this drug (40).
Toniati and colleagues in a single center study of 100 patients in Brescia, Italy prescribed 8mg/kg 
(max800mg) by two consecutive intravenous infusions 12 h apart. Based on the results of this 
study Tocilizumab was rapid, with sustained response and was associated with significant clinical 
improvement in patients with COVID-19. (33) In a retrospective study conducted by Alattar and 
colleagues in Qatar, 25 patients with COVID-19 received one to three median doses 4.8mg/kg. 
Result of this study showed that Tocilizumab decreased the inflammatory markers, improved 
radiological outcomes and reduced needs for ventilator support (34).
In a case report study of 61-year-old man with COVID-19, who underwent kidney transplantation, 
it was observed that 324 mg Tocilizumab via subcutaneous with hydroxychloroquine can 
successfully manage the infection (35).
On the other hand, in another study that was recently published, new impact of Tocilizumab 
administration on mortality in severe COVID-19 was assessed. Patients received several doses of 
Tocilizumab including 400 mg (96%), followed by 800 mg (1%), 8 mg/kg (1%), and 4 mg/kg 
(1%). Based on the results of this study, current analysis does not support the use of Tocilizumab 
for the management of cytokine storm in patients with COVID-19 and use of this drug should be 
limited (40).  
We estimate that many of studies haves mentioned positive effect of Tocilizumab in treatment of 
COVID-19 but recent studies doubt about its effects. 
Expert opinion
The probable reason for the serious deterioration and the loss of some organs in coronavirus 
disease are cytokines, known as cytokine release syndrome (CRS) (1, 27). Therefore, drugs used 
in the past for the CRS have been considered as effective drugs for treating patients with COVID-
19 (13). Recently Tocilizumab has been introduced to treat patients with COVID-19 and 
researchers are investigating further the efficacy of this drug for different patients (13). 
There are multiple RCTs in progress to evaluate the efficacy of Tocilizumab include 
NCT04320615, NCT04317092 and NCT04363853. (41) Based on the results of reviewed studies, 
many patients observed positive effect after prescribing this drug (13, 30-38). However, we cannot 
claim that Tocilizumab has approved and confirmed positive therapeutic effect on this viral 
disease.
Initial studies has been shown that Tocilizumab had reduced mortality and improved clinical 
manifestation in patients infected with coronavirus. (30-40) But recently, Andrew Tsai and 
colleagues published an article that debates the use of Tocilizumab should be limited to the context 
of a clinical trial until more evidence is available (40). Indeed, the researchers claimed there was 
no difference in mortality in patients treated with tocilizumab versus those receiving supportive 
care. However, a systematic review study conducted by Avi Kaye and Robert Siegel in Stanford 
University, investigating several other studies, concluded positive evidence for the potential 
efficacy of Tocilizumab resulting in less deaths. (42-44). According to the authors of this article, 
notable limitations such as different data of geographies, resources, demographics, and TCZ 
dosing amount, number and timing can affect the result of main conclusion. In this regard different 
studies have different participants, complementary drugs such as hydroxychloroquine, 
azithromycin, lopinavir/ritonavir, ribavirin, and/or interferon α2‐a, Meropenem, Azithromycin and 
dexamethasone, different doses (4, 8 mg/kg), different time (1,2,3) and different route (IV, SQ). 
Therefore, we can assert that continuous accurate protocol and method of treatment with 
Tocilizumab is not found and physicians prescribe this drug with trial and error. 
In some studies observed positive effect of Tocilizumab with combination of antiviral drugs such 
as lopinavir/ritonavir (400 mg/100 mg twice a day) or remdesivir 100 mg/day and corticosteroids 
able to improve clinical manifestations of patients. In this studies other drugs were different, for 
example in chinies and Italian clinical trials some drugs such as glucocorticoid, interferon α2, and 
antibiotic were used. Therefore, maybe antiviral drug, especially lopinavir/ritonavir (400 mg/100 
mg twice a day) with Tocilizumab reduced mortality in severe COVID-19 patients. 
Timing for prescribing Tocilizumab and selecting suitable patients for treatment is also an 
important question. All of the reviewed studies included patients in severe phase of disease. Some 
researchers claim that the optimal time to prescribing Tocilizumab is in beginning of inflammation 
and first steps of dropping O2 saturation. But still accurate time and infection stage to start this 
drug is unclear. 
Comparison the clinical differences between effective (30-40) and ineffective (47) treatments 
revealed the importance of time of administration and combination therapy with antivirals and 
Tocilizumab. In one clinical trial show ineffective treatment, Tocilizumab administer before the 
progression of respiratory failure and in patients who met the aforementioned criteria for disease 
severity. In this trial patient didn’t received any antiviral drug (47). Administration of Tocilizumab 
in the studies with effective results were combined with an antiviral drug and for patients with 
severe COVID-19.
There have been few reports about side effects after use of Tocilizumab. For example study of 
Campochiaro and colleagues Bacterial/fungal infection showed side effects only in 13% of patients 
who received this drug (42).In another study, Rojas-Marte and colleagues, reported bacteremia, 
fever, cough and shortness of breath (45). Majority of studies did not find any side effects after 
use of Tocilizumab in patients affected with COVID-19 until with twice prescribing  (46, 48). Due 
to the current pandemic situation and three speed of resource dissemination, there may be side 
effects but they are not reported. On the other hand, taking drugs at the same time makes it difficult 
to judge the side effects. 
We should know that Tocilizumab is not an anti-viral drug and may only be effective in a group 
of patients with inflammation and lung damage caused by the coronavirus. Another important 
point is that excessive production and activity of Tocilizumab can cause autoimmune diseases and 
damage body tissues (26-29). This drug is very sensitive and can be used in a specific age and 
certain patients. As a result of review of the published data and based on the mechanism of action 
of Tocilizumab, we may be able to claim that this drug can be a better or more suitable choice to 
be used for in patients with higher IL-6 level than normal. 
Although Tocilizumab has been accepted by China Health Commission and also recommended by 
some other health commissions all over the world, its positive effects cannot be predicted in all 
patients. 
Conclusion 
Tocilizumab may have a positive effect on improving immune damaging, lung functional injuries 
and arterial oxygen saturation. Researchers who had the successful experience of using this drug 
for treating inflammation lungs diseases, hope it will make effective and promising treatment to 
improve lung tissue inflammation in patients with fatal COVID-19 virus. However, further 
accurate clinical trial studies are needed to determine its efficacy in patients with specific 
characteristics such as age, level of IL-6, and different clinical symptoms. 
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 Tocilizumab is a suggested anti-inflammatory drug to treatment COVID-19
 Our study is immunopharmacology review that can be suitable for now
 Tocilizumab is effective treatment in patients with severe COVID-19
 Still accurate time and infection stage to start this drug is unclear
 Accurate clinical trial studies are needed to determine Tocilizumab efficacy
Table 1: Clinical outcomes of patients with Covid-19 after Tocilizumab therapy
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25 to 88 y
Clinical trial
4–8mg/kg (one dose) and 
400 mg through an IV drip 
up to a maximum of 800 
mg (3 dose)
antiviral therapy of lopinavir/ 
ritonavir (200/50 mg per tablet 
for adults twice a day, IFN-α (5 
million U each time for adults or 
equivalent dissolved in 2 mL of 
sterilized water and aerosol 
inhalation twice a day, ribavirin 
(recommended for use with IFN 
or lopinavir/ritonavir, 500 mg 
per dose for adults
glucocorticoid (use for a short 
period of time, range 3 to 5 d, as 
appropriate, at a dose not 
exceeding the equivalent of 1 to 
2 mg/kg per day 
methylprednisolone
tocilizumab is an effective 
treatment to reduce 
mortality
31 Tocilizumab, an 
anti-IL6 receptor 
antibody, to treat 
Covid-19-related 
respiratory






Case report 8 mg/kg  IV for each dose, 8 hours apart
lopinavir-ritonavir 400 mg-100 
mg orally
tocilizumab is an effective 
treatment to reduce lung 
inflammation
cytokine storm decreased 











study 80 to 600mg per time
Unclear
Single dose of TCZ seems 
to fail to improve the 
disease activity in critically 
ill patients although it was 
used in combination with 
glucocorticoid. However, 
repeated doses (even 
repeated with a lower dose) 
of TCZ might improve the 
condition of critically ill 
patients










Case report 8 mg/kg IV every 4 weeks 
Unclear a patient with insulin- 
dependent type 2 diabetes 
mellitus and SSc- ILD 





developed a mild form of 
COVID-19
34 Tocilizumab for 






failure: A single 
center study of 






Clinical trial 8mg/kg (max800mg) by two IV infusions 12 h apart
antiviral drugs (lopinavir 400 
mg + ritonavir 100 mg twice a 
day or remdesivir 100 mg/day), 
antibiotic prophylaxis 




The response to TCZ was 
rapid, sustained, and 






















associated with dramatic 
decline in inflammatory 
markers, radiological 



















Case report 324 mg SC
Meropenem, Azithromycin was 
administered orally for 3 days, 
Hydroxychloroquine, IVIG
the infection was 
successfully managed with 
the use of 
hydroxychloroquine and a 











8mg/kg  IV with a second 
dose 12hours after the first 
and a possible third dose 
after further 24‐36 hours 
(three dose)
Unclear Rapid relief of respiratory 
symptoms, resolution of 
fever, and reduction in CRP 
and no adverse events were 
registered 















a Sickle Cell Case report
8 mg/kg IV (one dose) Hydroxychloroquine Improvement in Patients 
condition and level of 
SPO2 after 3 days. 
39 Favorable 
changes of CT 







A 64 old 
man with  
Case report 8 mg/kg ( two doses) 
Unclear Improvement in chest CT 










198 patients Observational 
Study
400 mg (96%), followed 
by 800 mg (1%), 8 mg/kg 
(1%), 4 mg/kg (1%)
Unclear Tocilizumab demonstrated 
a trend association towards 












10 patients (15.1%) 
received 800 mg of 
tocilizumab, 3 patients 
(4.5%) received 600mg of 
tocilizumab, and 53 
patients (80.3%) received 
400 mg
Unclear 
The current analysis does 
not support the use of 
tocilizumab for the 
management of cytokine 
storm in patients with 
COVID-19. 
Use of this therapeutic 
agent should be limited to 
the context of a clinical trial 













Cohort study 400 mg IV 
hydroxychloroquine 400 mg 
daily, lopinavir/ritonavir 
400/100 mg twice daily, 
ceftriaxone 2 gr for 6 days, 
azithromycin 500 mg daily
This is the first study 
comparing tocilizumab to 
standard of care in severe 
COVID-19
Tocilizumab in severe 
COVID-19 patients did 
influence 28-day clinical 
outcomes
Tocilizumab safety was 
satisfactory except for ICU-
admitted patients














lower mortality in patients 
with severe to critical 
COVID-19 disease who 
received tocilizumab
but use of tocilizumab was 
associated with lower 
mortality in intubated 
patients













8 mg/kg IV (up to a 
maximum 800 mg per 
dose)
hydroxychloroquine (200 mg 
bid), azithromycin (500 mg 
once), prophylactic dose of low 
weight heparin, and 
methylprednisolone (a tapered 
dose of 1 mg/kg up to a 
maximum of 80 mg)
TCZ administration did not 
reduce ICU admission or 
mortality rate










44 patients Case- control Unclear 
Hydroxychloroquine, 




Tocilizumab group have 
improved survival outcome
COVID-19: corona virus disease -19 , TCZ: Tocilizumab, CRP: C-reactive protein, IVIG: intravenous immune globulin, SPO2:Saturation of Peripheral Oxygen, CT: 
Computed tomography, SSc: systemic sclerosis, IV: Intra venous, SC: Subcutaneous 

